Chondrosarcoma, a treatment-resistant cancer with limited therapeutic options, lacks
significant advancements in treatment methods. However, PR-619, a novel inhibitor of …

Prostate cancer is the second most commonly diagnosed cancer, and prostate cancer is the
second most common cause of cancer death in United States men after lung cancer. Many …

Chondrosarcoma, a heterogeneous malignant bone tumor, commonly produces cartilage
matrix, which generally has no response to conventional therapies. Studies have reported …

Chondrosarcoma is the second most common primary bone tumor and it responds poorly to
both chemotherapy and radiation treatment. In this study, we investigated the anticancer …

Bortezomib, formerly known as PS341, is a novel proteasome inhibitor with in vitro and in
vivo antineoplastic effects in many malignancies. However, diverse antitumor mechanisms …

Chondrosarcoma is a malignant soft tissue sarcoma with poor prognosis. Puerarin has been
demonstrated to possess anticancer properties; however, the effects of puerarin in human …

Background Osteosarcoma (OS) is a common malignant cancer in children and adolescents
and has a cure rate that has not improved in the last two decades. CYT997 (lexibulin) is a …

Developing novel therapeutic agents against chondrosarcoma is important. SF2523 is a
PI3K-Akt-mTOR and bromodomain-containing protein 4 (BRD4) dual inhibitor. Its activity in …

Osteosarcoma (OS) is the predominant form of primary bone malignancy in children and
adolescents. Although the combination of chemotherapy and modified surgical therapy …

Background Paclitaxel is a chemotherapeutic drug for cancer, which is isolated from the
Pacific yew tree. However, and the molecular mechanism and the antitumor effects of …